论文部分内容阅读
目的探讨HER-2/neu胞外配体第2结构域(RLD2)作为肿瘤疫苗在抗乳腺癌免疫中的作用。方法纯化出目的蛋白HER-2/neu胞外配体第2结构域,同时选取10例经免疫组化证实为HER-2/neu阳性的乳腺癌,用RLD2分别负荷这10名患者外周血来源的树突状细胞(DC),再诱导抗原特异的细胞因子诱导的杀伤细胞(CIK),将DC与C IK共培养,研究其对HER-2/neu阳性、阴性肿瘤细胞株和自体乳腺癌细胞杀伤活性的作用。结果RLD2诱导的特异性CIK对HER-2/neu阳性肿瘤细胞SKBR-3以及自体乳腺癌细胞的杀伤活性,较之单独CIK组更高,差异有统计学意义(P<0.01);RLD2诱导的特异性C IK对HER-2/neu阴性细胞MDA-435的杀伤活性与单独C IK组之间差异无统计学意义(P>0.05)。结论负载RLD2的DCs诱导的C IK对HER-2/neu阳性肿瘤细胞以及自体乳腺癌肿瘤有特异性杀伤能力,RLD2可能成为新型肿瘤疫苗应用于临床乳腺癌免疫治疗。
Objective To investigate the role of HER-2 / neu extracellular ligand domain 2 (RLD2) as a tumor vaccine against breast cancer. Methods The second domain of HER-2 / neu extracellular ligand was purified and ten HER-2 / neu-positive breast cancers confirmed by immunohistochemistry were selected. The peripheral blood of 10 patients (DCs) and then induced antigen-specific cytokine-induced killer cells (CIKs). DCs were cocultured with C IK to study their effect on HER-2 / neu negative, negative tumor cell lines and autoimmune breast cancer The role of cell killing activity. Results The specific cytotoxicity of CIK induced by RLD2 was significantly higher in HER-2 / neu-positive SKBR-3 and autologous breast cancer cells than CIK alone (P <0.01) The killing activity of specific C IK to HER-2 / neu negative cells MDA-435 was not significantly different from that of C IK alone (P> 0.05). Conclusions C IK induced by DCs loaded with RLD2 has specific killing ability on HER-2 / neu positive tumor cells and auto-breast cancer tumors. RLD2 may be a new tumor vaccine for clinical breast cancer immunotherapy.